December #42 : A B.i.d. for Easier Adherence - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

The Age of Ignorance

Reboot Your System

POZ Annual Givers Guide

POZ Annual Givers Guide, Part 2

A Happy Convert

Working Mom

Money Man

You Can Take It With You

LifeStyle Change

Mom Knows Best

Foul Ball


To the Editor


Don't Ask, Do Tell?

In Your Wildest Steams

Boys in Green

When This You See

Ab-Fab Babs

Say What

POZarazzi: Random Harvest

Pirate of Penance

Show and Tell

hiv and Me

How Am I?

A Bite of the Apple

Down-and-Dirty Markups

Grow Your Own Bacteria

The Rx Files

Beyond Grapefruit Juice

Douching Dangers

Therapeutic Vaccine in the Works

A B.i.d. for Easier Adherence

Nevirapine for Best Head

Strong in the Tooth

Buyers Clubs

Where to Find It

Pair of Aces

Aunt Evelyn's Letters

POZ Picks

Letter from Sri Lanka: Island Fever

Wrong Way on the ADA

Mann of the Hour


Talk to the Hand

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 1998

A B.i.d. for Easier Adherence

by Tim Horn

Besieged by unforgiving pill-popping schedules, many PWAs are wishing for a kinder, gentler regimen: if only drugs could be taken twice (b.i.d.) instead of three times (t.i.d.) daily…. But—bottom line—can less-frequent dosing maintain adequate blood levels of the drugs for virus-suppressing potency? Results from studies so far have been mixed.

First, the good news: A recent trial of 360 PWAs on combos containing nelfinavir (Viracept) found that equal proportions of patients (80 percent) on t.i.d. or b.i.d. had undetectable viral loads after 48 weeks. Side effects were also about equal, with slightly more cases of diarrhea in the b.i.d. group. And preliminary results from 242 patients in a 24-week saquinavir (Fortovase) combo study found roughly similar rates of undetectability among b.i.d.’ers and t.i.d.’ers (69 percent vs. 74 percent)—but whether these results will hold up in more people over the long term is unknown.

The bad news concerns indinavir (Crixivan). Expectations were raised last winter when a 90-person, 24-week study found roughly equal viral suppression in those on the drug (as part of a combo) either b.i.d. or t.i.d. for 24 weeks. But these hopes were dashed by a 400-person study, halted in September when researchers saw that after the same period, only 64 percent of b.i.d.’ers had undetectable viral loads, compared to 91 percent of t.i.d.’ers. Manufacturer Merck then issued a warning against using the b.i.d. regimen.

Meanwhile, research involving two-protease combos (plus nucleosides) taken b.i.d. is underway. 

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.